VTGN - Undervalued VistaGen Therapeutics Analyst Highlights Potential In Anxiety Treatment | Benzinga
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other mental health conditions.
The lead product Fasedienol (PH94B), is an intranasal pherine and is in late-stage development for SAD, which affects about 10% of the U.S. population, with 6 million adults being treated by a physician.
Related Content: Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst.
Aside from one negative Phase 3 study, PALISADE-1, which was ...